Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

Ingrezza (valbenazine) is prescribed to treat the following conditions in adults: tardive dyskinesia (TD) chorea due to Huntington’s disease; About tardive dyskinesia. TD causes involuntary ...

Ingrezza (in-GREH-zah) was approved in 2017 as the first medicine to help control movement in people with tardive dyskinesia and was approved for use in people with chorea caused by Huntington’s ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat tardive dyskinesia and chorea caused by Huntington’s disease. Ingrezza can cause mild to serious side effects. Examples ...

Ingrezza has possible interactions with some other drugs, including antidepressants and antiepileptics (medications used to treat seizures). Ingrezza also interacts with certain supplements.

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions.

Ingrezza (valbenazine) is a brand-name oral capsule prescribed for tardive dyskinesia and Huntington’s chorea. The cost of the drug with and without insurance can depend on several factors. As ...

Management guided INGREZZA sales to reach between $2.5 billion and $2.6 billion in 2025, supported by an expanded sales force and ongoing direct-to-consumer initiatives.

SAN DIEGO, July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA ® (valbenazine) capsules, the #1 ...

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions.

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American ...